These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22358188)

  • 41. A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients.
    Andrews LM; Hesselink DA; van Schaik RHN; van Gelder T; de Fijter JW; Lloberas N; Elens L; Moes DJAR; de Winter BCM
    Br J Clin Pharmacol; 2019 Mar; 85(3):601-615. PubMed ID: 30552703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Basiliximab: a review of its use as induction therapy in renal transplantation.
    Chapman TM; Keating GM
    Drugs; 2003; 63(24):2803-35. PubMed ID: 14664658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Towards graft-specific immune suppression: Gene therapy of the transplanted kidney.
    Sandovici M; Deelman LE; Benigni A; Henning RH
    Adv Drug Deliv Rev; 2010 Nov; 62(14):1358-68. PubMed ID: 20688115
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunosuppression in live-related donor renal transplantation.
    Iman A; Rao M; Juneja R; Jacob CK
    Natl Med J India; 2001; 14(2):75-80. PubMed ID: 11396322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study.
    Webb NJA; Baumann U; Camino M; Frauca E; Undre N;
    Pediatr Transplant; 2019 Feb; 23(1):e13328. PubMed ID: 30665258
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Graft function based on two hours peak level monitoring of cyclosporine A during the first six months of renal transplantation.
    Hami M; Naghibi M; Mojahedi MJ; Sharifipour F; Shakeri MT
    Saudi J Kidney Dis Transpl; 2012 Nov; 23(6):1169-74. PubMed ID: 23168844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus.
    MacDonald A; Scarola J; Burke JT; Zimmerman JJ
    Clin Ther; 2000; 22 Suppl B():B101-121. PubMed ID: 10823378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Modern immunosuppression following renal transplantation. Standard or tailor made?].
    Budde K; Giessing M; Liefeldt L; Neumayer HH; Glander P
    Urologe A; 2006 Jan; 45(1):9-17. PubMed ID: 16328215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tacrolimus: a further update of its use in the management of organ transplantation.
    Scott LJ; McKeage K; Keam SJ; Plosker GL
    Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
    Tett SE; Saint-Marcoux F; Staatz CE; Brunet M; Vinks AA; Miura M; Marquet P; Kuypers DR; van Gelder T; Cattaneo D
    Transplant Rev (Orlando); 2011 Apr; 25(2):47-57. PubMed ID: 21190834
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunosuppression and immune monitoring after renal transplantation.
    Zand MS
    Semin Dial; 2005; 18(6):511-9. PubMed ID: 16398715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update in immunosuppression.
    Huizinga R
    Nephrol Nurs J; 2002 Jun; 29(3):261-7. PubMed ID: 12164076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0.
    Loichot C; Bentue-Ferrer D; Bernard N; Bonardet A; Boulieu R; Kergueris MF; Paintaud G; Peytavin G; Simon N; Marquet P;
    Fundam Clin Pharmacol; 2006 Feb; 20(1):91-6. PubMed ID: 16448399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Current and evolving immunosuppressive regimens in kidney transplantation.
    Gaston RS
    Am J Kidney Dis; 2006 Apr; 47(4 Suppl 2):S3-21. PubMed ID: 16567239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenomics: the key to improved drug therapy in transplant patients.
    Burckart GJ
    Clin Lab Med; 2008 Sep; 28(3):411-22, vi. PubMed ID: 19028260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. THE CHALLENGE OF ACHIEVING ADEQUATE ORAL IMMUNOSUPPRESSION IN A RENAL TRANSPLANT RECIPIENT WHO DEVELOPS SHORT BOWEL SYNDROME (SBS).
    McCloskey OM; Woodman A; Mitchell A; Smyth J
    Ulster Med J; 2018 Oct; 87(3):200-201. PubMed ID: 31061546
    [No Abstract]   [Full Text] [Related]  

  • 58. [Immunosuppressive agents in pediatric renal transplantation].
    Ismaili K; Abramowicz D; Adams B; Godefroid N; Lolin K; Schurmans T; Hall M; Janssen F
    Rev Med Brux; 2005; 26(6):505-12. PubMed ID: 16454154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progress in transplantation.
    Levy GA
    Ther Drug Monit; 2010 Jun; 32(3):246-9. PubMed ID: 20418803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circumscribed nodule in a renal transplant patient.
    Berger AP; Little AJ; Wanat KA
    Cutis; 2016 Aug; 98(2):81;98;100. PubMed ID: 27622257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.